Providing New Hope
Code Bio is developing next-generation gene therapies for patients with rare and prevalent genetic diseases
Code Bio is an emerging next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Leveraging our novel proprietary multivalent synthetic DNA delivery platform, 3DNA, we can overcome many of the challenges inherent with viral based gene therapies, such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. We are advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases.
Our 3DNA platform is engineered to overcome serious limitations and liabilities of current gene therapies, by enabling delivery of large genes, improving cellular targeting, and more.
We are advancing an internal pipeline of gene therapies to treat rare diseases with initial programs focused on treating Duchenne Muscular Dystrophy (DMD) and Type 1 Diabetes (T1D).
Partner with Us
We are actively engaged in establishing partnerships to take forward strategic programs that hold promise for rare and prevalent diseases.